CAS 149155-01-1: 9H-Xanthen-9-one,1,3,6-trihydroxy-2-(3-hydroxy-3-methylbutyl)-7-methoxy-8-(3-methyl-2-buten-1-yl)-

Cratoxylone is a bioactive compound, which is derived from specific plant sources predominantly found in certain tropical regions. The compound exhibits a complex molecular structure that acts primarily via modulating specific biological pathways associated with inflammation and cellular stress response. Its mode of action involves the inhibition of particular enzyme activities and signaling pathways, which play a critical role in various physiological processes and pathological conditions. Cratoxylone has garnered significant interest in the scientific community due to its potential therapeutic applications in treating chronic inflammatory diseases and as a possible adjunct in cancer therapy. Researchers are exploring its efficacy and mechanism further through advanced in vitro and in vivo studies. The compound's integration into therapeutic regimes could herald new approaches in managing diseases characterized by inflammation and abnormal cell proliferation. Its continued study may contribute to the development of novel pharmacological agents with improved specificity and reduced side effects compared to traditional therapies.

Cratoxylone exhibits potent activity in vitro against Plasmodium falciparum chloroquine-resistant strain W2, with the IC₅₀ value belows 3 uM.

Cratoxylone is derived from the bark of the Cochin tree and has anti-plasmodial activity and potential anti-tumor and antioxidant activity.

Cratoxylone